HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma (ATNM) with a maintained price target of $50.
March 19, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharma maintains a Buy rating from HC Wainwright & Co. with a price target of $50, as per analyst Joseph Pantginis.
The reiteration of a Buy rating and a high price target of $50 by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ATNM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100